Skip to content
    COR
    Earnings call· Jun 2026(Q3 FY26)

    Cencora Q3 FY26 earnings call COR

    Aug 5, 2026 Source

    Executive summary

    Cencora Q3 FY26 — Strong Specialty Performance Drives Double-Digit Operating Income and Raised EPS Guidance

    Cencora delivered strong Q3 FY26 results, driven by robust specialty pharmaceutical performance, particularly within its MSO platforms, and effective capital deployment. The company raised its full-year adjusted EPS guidance, reflecting confidence in its pharmaceutical-centric strategy and continued execution, despite headwinds from manufacturer list price reductions. Management remains focused on digital transformation and talent development to sustain long-term growth.

    Highlights

    5

    • Adjusted operating income grew 17% to $1.2 billion, driven by U.S. Healthcare Solutions and International segments.

    • Adjusted EPS grew 12%, leading to raised fiscal 2026 guidance to $17.75-$17.95, supported by $1 billion in share repurchases.

    • U.S. Healthcare Solutions segment operating income increased 16% to $966 million, with strong performance from MSO platforms (One Oncology, RCA).

    • International Healthcare Solutions operating income grew 21% (23% constant currency) to $166 million, driven by European distribution and specialty logistics.

    • GLP-1 sales increased by $2.3 billion year-over-year, contributing to U.S. revenue growth.

    Concerns

    3

    • Manufacturer list price reductions represented a $2.4 billion headwind to U.S. revenue growth.

    • Net interest expense increased by $59 million to $141 million, primarily due to debt for the One Oncology acquisition.

    • Potential $0.35 EPS headwind in FY27 from the MWI Animal Health divestiture if closed at the midpoint of the fiscal year.

    Guidance & targets

    14
    CategoryTargetConfidence
    Adjusted EPS
    $17.75 to $17.95
    high materiality
    High
    Adjusted Free Cash Flow
    approximately $3 billion
    medium materiality
    High
    U.S. Healthcare Solutions Revenue Growth
    lower half of our 4% to 6% growth range
    medium materiality
    Medium
    International Healthcare Solutions Revenue Growth (as reported)
    approximately 8%
    medium materiality
    Medium
    International Healthcare Solutions Revenue Growth (constant currency)
    approximately 7%
    medium materiality
    Medium
    Other Segment Revenue Growth
    approximately 6%
    low materiality
    Medium
    Consolidated Operating Income Growth
    13% to 14%
    high materiality
    High
    U.S. Healthcare Solutions Segment Operating Income Growth
    14.5% to 15.5%
    high materiality
    High
    International Healthcare Solutions Segment Operating Income Growth (as reported and constant currency)
    approximately 9%
    medium materiality
    Medium
    Other Segment Operating Income Growth
    approximately 10%
    low materiality
    Medium
    Net Interest Expense
    approximately $490 million
    medium materiality
    Medium
    Diluted Shares Outstanding
    approximately 194 million shares
    medium materiality
    Medium
    EPS Headwind from MWI Animal Health Divestiture
    approximately $0.35
    high materiality
    High
    MWI Animal Health Operating Income Headwind
    $150 million
    medium materiality
    High

    Segment performance

    3
    SegmentRevenueYoYQoQMargin
    U.S. Healthcare Solutions
    Revenue growth supported by strength in specialty across health systems and physician practices, and $2.3 billion year-over-year increase in GLP-1 sales. Growth offset by $2.4 billion manufacturer list price reductions, 2025 oncology customer loss, and lower sales to a large mail order customer. Operating income growth driven by MSOs (One Oncology, RCA) performing ahead of expectations and double-digit organic operating income growth when excluding One Oncology contribution and customer loss.
    Operating income growth: 16%
    		$74.9 billion5%—$966 million
    International Healthcare Solutions
    Revenue growth driven by European distribution and specialty logistics businesses (World Courier, European 3PL). European distribution benefited from the shift in timing of manufacturer price adjustments in a developing market country. Strong performance across global specialty logistics and European 3PL businesses.
    Operating income growth (as-reported): 21%Operating income growth (constant currency): 23%
    		$7.7 billion6%—$166 million
    Other
    Revenue growth largely due to Pro Pharma and MWI Animal Health. Operating income growth at MWI Animal Health also benefited from being accounted for as held for sale.
    Operating income growth: 25%
    		$2.3 billion7%—$109 million

    Operational metrics

    13
    Consolidated Revenue Growth
    5%YoY
    Q3 FY26

    Driven by growth in both reportable segments and in other.

    Consolidated Adjusted Gross Profit
    $3.5 billionup 23%
    Q3 FY26

    Primarily due to growth in the U.S. Healthcare Solutions segment.

    Consolidated Gross Profit Margin
    4.16%expanded by 61 basis points
    Q3 FY26

    Largely due to our acquisition of One Oncology in February.

    Consolidated Adjusted Operating Expenses
    $2.3 billionincrease of 27%
    Q3 FY26

    Reflects the impact of the February 2026 acquisition of One Oncology.

    Net Interest Expense
    $141 millionincrease of $59 million
    Q3 FY26

    Primarily due to the debt raised in February to finance the One Oncology acquisition.

    Effective Income Tax Rate
    19.9%compared to 20.7% in the prior year quarter
    Q3 FY26
    Diluted Share Count
    193.9 million0.7% decrease compared to the prior year quarter
    Q3 FY26

    As a result of $1 billion of share repurchases in the quarter at an average price of $268 per share.

    Cash and Investments Balance
    $2.8 billion
    June 30, 2026

    Ended June with $2.8 billion of cash.

    GLP-1 Sales
    increased by $2.3 billionyear-over-year
    Q3 FY26

    Contributed to U.S. revenue growth. Generally in line with expectations.

    Manufacturer List Price Reductions
    $2.4 billion
    Q3 FY26

    Represented a headwind to revenue growth.

    RCA Financing-Related Term Loan Repayment
    $800 million
    Q3 FY26 and July 2026

    Fully paid off our RCA financing-related term loan balance.

    Share Repurchases
    $1 billion
    Q3 FY26

    Opportunistic share repurchases contributed to EPS growth.

    MWI Animal Health Underlying Growth
    10%
    Q3 FY26

    Underlying MWI delivered about 10% growth.

    Industry KPIs

    4
    MetricValueDetails
    Utilization trendssequential rebound
    Pharmacy scripts specialtyincreased by $2.3 billionUSD
    Segment revenue operating incomeU.S. Healthcare Solutions revenue: $74.9 billion; International Healthcare Solutions revenue: $7.7 billion; Other revenue: $2.3 billionUSD
    Adjusted EPS EBITDA leverage guidance$1.2 billionUSD

    Deals & partnerships

    2
    One OncologyAcquisition of oncology management services organization (MSO).

    Acquisition closed in February 2026, driving adjusted operating income growth and gross profit margin expansion. Performance ahead of expectations.

    CovetrusAgreement to merge MWI Animal Health with Covetrus.

    Continuing to work through the regulatory process; no update on timing. Structure includes upfront cash, preferred equity, and common equity.

    Risks & headwinds

    5
    Manufacturer List Price ReductionsQ3 FY26

    $2.4 billion headwind to revenue growth

    Mitigation: Value proposition of services remains clear; well positioned through distribution footprint, sourcing scale, and end-to-end channel relationships.

    Increased Net Interest ExpenseQ3 FY26

    Increased by $59 million to $141 million

    Mitigation: Significant progress on debt repayment commitments, fully paid off RCA financing-related term loan balance of $800 million.

    MWI Animal Health Divestiture EPS HeadwindFY27

    Approximately $0.35 EPS headwind

    Mitigation: Partially offset by upfront cash, preferred equity, and common equity from the transaction structure.

    Stronger Dollar Impact on International RevenueSecond half of FY26

    International Healthcare Solutions revenue growth revised to approximately 8% (from previous low end of range)

    Mitigation: Constant currency growth still expected at approximately 7%.

    340B Program ChangesOngoing assessment

    Discussed, not quantified

    Mitigation: Assessing new guidance, engaging with regulators and legislators to monitor potential unintended consequences, focusing on patient access and cost-effectiveness; confident that physician reimbursement will not be negatively impacted.

    What to watch in Q4 FY26

    4

    FY27 Outlook

    November earnings call
    CurrentCurrently in the midst of our fiscal 2027 planning process
    TargetFull fiscal year '27 guidance

    Why it matters

    Provides the first official outlook for the next fiscal year, crucial for investor modeling and understanding future growth trajectory.

    Looking ahead to fiscal 2027, we are currently in the midst of our fiscal 2027 planning process and will provide full fiscal year '27 guidance on our November earnings call.

    Q&A highlights

    5

    What drove the reacceleration in the U.S. pharma business this quarter, and is management comfortable with the Street's 14% growth estimate for FY27?

    Eva Boratto attributed U.S. outperformance to strength in MSOs (One Oncology, RCA) and underlying core business trends, with double-digit organic operating income growth excluding One Oncology contribution and customer loss. Bob Mauch reiterated confidence in long-term guidance but declined to comment on specific Street estimates for FY27.

    “Excluding the loss, as you said, of Florida Cancer and the contribution from One Oncology, our operating income growth was up double digits, a meaningful acceleration from the 7% last quarter.”

    asked by Lisa Gill · answered by Eva Boratto

    2 min read5 chapters

    Detailed Narrative

    01

    Specialty Pharmaceutical Platform

    Cencora's differentiated specialty platform supports growth across the healthcare ecosystem, leveraging its strong foundation in pharmaceutical distribution and deep relationships with providers and manufacturers. The company's management services organizations (MSOs) like One Oncology and RCA help oncology and retina practices manage complexity, broaden access to clinical trials, and maintain focus on patient care. Both MSO platforms performed ahead of expectations, demonstrating strength in attracting physicians.

    02

    Digital Transformation Initiatives

    Cencora is undergoing a digital transformation, combining business process improvement and technology advances, including AI, to modernize operations. An example is using AI for demand forecasting to improve planning, enhance product availability, and maintain reliable service for providers and pharmacies. This disciplined approach is applied across the organization to simplify routine activities and provide better insights to team members.

    03

    Talent and Culture Focus

    The company is focused on talent and culture, ensuring clear career paths and strengthening execution capabilities. Recent executive appointments, including Eva Boratto as CFO and Sam Hammock as CHRO, are highlighted as bringing valuable expertise to the enterprise leadership team. This focus aims to equip teams with the skills, resources, and leadership needed to advance the pharmaceutical-centric strategy.

    04

    Biosimilar Strategy and Impact

    Cencora views biosimilars as beneficial for patients, cost reduction, and patient access, representing an incremental positive for profit. While Part D biosimilars offer less service opportunity, Part B biosimilars, particularly in the buy-and-bill infusion space supported by MSOs and GPOs, present a larger profit opportunity due to the extensive wraparound services provided. The company feels confident about the durability of this opportunity over the long term⏳.

    05

    MSO Value Creation Phases

    The MSO strategy involves three phases of value creation: integration of MSOs into Cencora (significant progress), sharing capabilities across the platform (early days💬 for clinical trials, especially in One Oncology), and developing new services (future focus on analytics and insights). This strategy is underpinned by the continuous addition of physicians to both RCA and One Oncology platforms through tuck-ins and individual physician recruitment.

    AI-generated summary of the company’s earnings call. Not investment advice.